share_log

Structure Therapeutics Doses First Patients In Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist GSBR-1290 In Obesity

Benzinga ·  Nov 14 05:04
Structure Therapeutics Doses First Patients In Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist GSBR-1290 In Obesity
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment